The Science of AOD-9604 Peptide: What Research Shows

Qualified researchers and analytical labs investigating metabolic peptides increasingly encounter AOD-9604 in the literature. But what exactly is this compound, and what does the science actually say about it? At PeptideValidation.com, we supply research-grade AOD-9604 as a 2 mg lyophilized powder specifically designed for controlled laboratory analysis. This article breaks down the molecular background, the analytical testing methods used to characterize it, and the quality standards that matter for reproducible research outcomes.

What Is AOD-9604?

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically amino acids 176 to 191. Researchers study it for its molecular interactions in metabolic and lipolytic pathways. It is used exclusively in controlled laboratory settings and is not approved for human or veterinary use.

AOD-9604 stands for Anti-Obesity Drug 9604. The name reflects its origins in early research exploring growth hormone fragments and their metabolic signaling properties. The compound corresponds to amino acids 176 to 191 on the human growth hormone sequence, a region that researchers identified as biologically distinct from the growth-promoting domain.

Because it is a fragment rather than the full 191-amino-acid growth hormone molecule, AOD-9604 has a much smaller molecular weight, sitting at approximately 1,817 daltons. That smaller size makes it practical to produce synthetically with high purity and to characterize thoroughly using standard analytical techniques like High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS).

In laboratory studies, researchers have examined how this peptide fragment interacts with beta-3 adrenergic receptors and fat cell signaling pathways. These interactions are the central subject of most published AOD-9604 research. It is worth noting clearly: this compound is intended exclusively for in vitro and controlled research applications. Qualified researchers at institutions and analytical labs are its primary audience, not clinicians or end consumers.

PeptideValidation.com supplies AOD-9604 as a 2 mg lyophilized powder. The lyophilized form preserves structural integrity during shipping and storage, which is critical when researchers need consistent starting material for repeated experimental runs.

Molecular Structure and Key Properties

AOD-9604 is a 16-amino-acid peptide with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, featuring a disulfide bond between cysteine residues at positions 7 and 14 that stabilizes its three-dimensional conformation.

The specific sequence of AOD-9604 is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. That 16-residue chain contains two cysteine residues that form an internal disulfide bridge. This bridge is structurally important: it locks the peptide into a conformation that researchers believe is necessary for its receptor-binding behavior.

The molecular formula is C78H123N23O23S2, and the molecular weight, as confirmed by mass spectrometry in correctly characterized batches, lands at approximately 1,817.08 daltons. These values are the first checkpoints a researcher should verify on any Certificate of Analysis (COA) before proceeding with an experiment.

Solubility is another key property. AOD-9604 dissolves readily in aqueous buffers at physiological pH ranges, which makes it compatible with common in vitro assay systems. Researchers typically reconstitute lyophilized AOD-9604 in sterile water or dilute acetic acid solutions, depending on the specific assay protocol.

Stability data from published studies suggest the lyophilized powder form retains structural integrity for extended periods when stored at -20 degrees Celsius away from light and moisture. Once reconstituted, the peptide should be used promptly or stored at 4 degrees Celsius for short-term use only. The 2 mg lyophilized format from PeptideValidation.com is designed with exactly these storage requirements in mind, giving labs a consistent and handleable unit size for analytical work.

What the Published Research Covers

Published research on AOD-9604 has examined its interactions with beta-3 adrenergic receptors, its effects on lipolysis in adipocyte cell models, and its metabolic signaling properties in animal studies, primarily in rodent models between 1996 and the early 2010s.

Most peer-reviewed work on AOD-9604 emerged from Australian research groups in the late 1990s and early 2000s, with a cluster of studies published between 1996 and 2012. Early animal studies used rodent obesity models to observe how the peptide affected fat metabolism at the cellular level. These studies measured changes in lipolysis rates and body composition in controlled conditions.

In adipocyte cell line experiments, researchers observed that AOD-9604 appeared to stimulate lipolysis (the breakdown of stored fat) and inhibit lipogenesis (the synthesis of new fat) through pathways that involve beta-3 adrenergic receptor signaling. The exact mechanism is still a subject of ongoing research interest, and no consensus has been established in human clinical contexts.

Human clinical trials in the early 2000s, including a Phase 2 trial conducted in Australia, explored safety and tolerability in obese adults. That trial reported an acceptable short-term safety profile, though the program was eventually discontinued before Phase 3 completion. Researchers citing these trials should access the original publications directly for methodology details rather than relying on secondary summaries.

It is important to read this research literature carefully. Many published studies used formulations and dosing protocols that differ from today's research-grade materials. When setting up a new experiment, researchers should calibrate their protocols to the specific batch purity and concentration documented in the COA for the material they are using, not assumed values from older literature.

Analytical Testing: How Labs Characterize AOD-9604

Standard analytical characterization of AOD-9604 includes HPLC purity assessment (targeting >98%), mass spectrometry for molecular weight confirmation, amino acid analysis for sequence verification, and where required, microbial screening and endotoxin testing for cell-based assays.

Reliable AOD-9604 research depends on well-characterized starting material. Four analytical methods form the core of a rigorous quality verification workflow.

HPLC Purity Analysis. Reversed-phase HPLC is the standard method for assessing peptide purity. A well-characterized research-grade batch should show purity at or above 98%, with a clearly documented chromatogram. Broad or poorly resolved peaks are a red flag.

Mass Spectrometry (MS). Electrospray ionization MS or MALDI-TOF confirms the molecular weight of the peptide and checks for truncation or modification artifacts that would not be detectable by HPLC alone. The confirmed mass should match the theoretical value of approximately 1,817.08 daltons within accepted instrument tolerance.

Amino Acid Analysis. This step verifies the composition of the peptide at the residue level. It catches substitution errors that can occur during solid-phase peptide synthesis and that MS alone might miss in certain cases.

Microbial and Endotoxin Screening. For cell-based assays, endotoxin contamination can confound results significantly. A COA from a responsible supplier will include Limulus Amebocyte Lysate (LAL) endotoxin data and, where appropriate, bioburden results.

Researchers reviewing a COA for AOD-9604 should confirm that all four data categories are present and that the lab issuing the certificate is an independent third-party facility, not the manufacturer testing its own product. Batch-specific documentation is non-negotiable for experimental reproducibility.

Storage, Reconstitution, and Handling in the Lab

Store lyophilized AOD-9604 at -20 degrees Celsius in a desiccated, light-protected environment. Reconstitute with sterile water or 0.1% acetic acid, use within 24 to 48 hours if kept at 4 degrees Celsius, and avoid repeated freeze-thaw cycles to preserve peptide integrity.

Correct handling of AOD-9604 before and after reconstitution is as important as obtaining a high-purity batch. Errors at this stage can introduce variability that undermines months of experimental work.

For long-term storage, keep the lyophilized powder at -20 degrees Celsius in a sealed vial with a desiccant. Avoid storing it in a frost-free freezer, which cycles temperature regularly and accelerates degradation. Light exposure can also degrade the disulfide bond, so amber vials or opaque storage containers are worth using.

For reconstitution, sterile water is appropriate for many applications. If the peptide does not dissolve cleanly at neutral pH, adding dilute acetic acid (0.1% to 1%) typically improves solubility without affecting the disulfide bond structure. Researchers should prepare only the volume needed for immediate use.

Once reconstituted, store the solution at 4 degrees Celsius and use within 24 to 48 hours. Repeated freeze-thaw cycles fragment the peptide chain and reduce effective purity. If you need to store reconstituted material longer, single-use aliquots frozen at -80 degrees Celsius are a practical option, though even this format has limits.

The 2 mg lyophilized format offered by PeptideValidation.com aligns with these handling requirements. A 2 mg unit is small enough to avoid waste on a single experiment and large enough to support multiple assay conditions without requiring excessive reconstitution steps. Consistent starting unit sizes also make it easier to compare results across experimental runs and between labs.

Why COA Verification Matters for AOD-9604 Research

A complete AOD-9604 Certificate of Analysis should include: peptide identity confirmation, HPLC purity percentage, mass spectrometry molecular weight data, batch and lot number, synthesis date, recommended storage conditions, and independent third-party laboratory contact information.

COA verification is not a bureaucratic checkbox. It is the foundation of experimental reproducibility. For a peptide like AOD-9604, where the disulfide bond is critical to its structural form, a COA that only reports purity by HPLC is insufficient on its own.

When reviewing a COA, check that the reported molecular weight matches the theoretical value for AOD-9604 to within the instrument's measurement uncertainty, typically plus or minus 0.1 daltons for modern instruments. Any significant deviation suggests a different compound, a truncated sequence, or a modification introduced during synthesis.

Check also that the batch number on the COA matches the batch number on the vial label. This sounds obvious, but mismatches do occur, particularly with resellers who may not handle original documentation carefully. The issuing laboratory should be independently identifiable, with a verifiable address and contact information.

Purity should be reported as a percentage with a chromatogram attached, not as a bare number. Ask the supplier for the raw chromatogram data if it is not included. Legitimate suppliers will provide it without hesitation.

For a broader look at quality standards, vendor certification criteria, and how to evaluate suppliers across all these dimensions, the full research guide on AOD-9604 peptide at PeptideValidation.com covers the complete picture. Understanding what separates a verified vendor from an unverified one is especially useful for labs setting up long-term research programs that depend on batch-to-batch consistency.

Regulatory and Ethical Context for AOD-9604 Research

AOD-9604 is classified as a research compound in most jurisdictions, meaning it is legal to purchase and study for in vitro and controlled laboratory purposes but is not approved for human or veterinary clinical use. Researchers must comply with applicable institutional, national, and local regulations governing peptide research compounds.

Understanding the regulatory status of AOD-9604 is essential before any procurement decision. In the United States, AOD-9604 is not approved by the FDA for any human or veterinary indication. It is classified as a research compound, which means its purchase and use are legally permissible for qualified researchers working in approved laboratory settings, subject to applicable regulations.

In Australia, where much of the foundational research was conducted, AOD-9604 has been listed as a Schedule 4 prescription medicine in certain formulations, which reflects a different regulatory environment than research-only purchase in the U.S. context. Researchers outside the U.S. should verify the specific rules in their jurisdiction before ordering.

Institutional oversight matters too. Labs affiliated with universities or research hospitals typically need to document the purpose of peptide purchases and may require institutional review board (IRB) or ethics committee notification depending on the study design. Even for purely in vitro work, keeping clear records of intended use, storage conditions, and disposal methods is standard good practice.

At PeptideValidation.com, AOD-9604 is supplied exclusively for laboratory research use. The product is not labeled, marketed, or sold for human consumption or therapeutic application. Researchers are responsible for ensuring their use complies with all applicable laws, institutional policies, and safety protocols. This framework protects both the integrity of the science and the researchers conducting it.

For the complete context on vendor evaluation, testing documentation standards, and how to structure a compliant AOD-9604 research workflow, see the comprehensive AOD-9604 research guide available on our blog.

Frequently asked questions

What is AOD-9604 peptide?

AOD-9604 is a synthetic 16-amino-acid peptide fragment derived from the C-terminal region (amino acids 176 to 191) of human growth hormone. It has a molecular weight of approximately 1,817 daltons and contains a disulfide bond between two cysteine residues. It is used exclusively in controlled laboratory research settings and is not approved for human or veterinary use.

What does AOD-9604 research focus on?

Published research on AOD-9604 has primarily examined its interactions with beta-3 adrenergic receptors and its effects on lipolysis and lipogenesis in adipocyte cell models and rodent studies. Most peer-reviewed work was published between 1996 and 2012, originating largely from Australian research groups. Human clinical data is limited and does not support therapeutic conclusions.

How should AOD-9604 be stored in a laboratory setting?

Lyophilized AOD-9604 should be stored at -20 degrees Celsius in a sealed, desiccated, light-protected container. Once reconstituted in sterile water or 0.1% acetic acid, the solution should be used within 24 to 48 hours if kept at 4 degrees Celsius. Repeated freeze-thaw cycles degrade the peptide and should be avoided.

What should a Certificate of Analysis for AOD-9604 include?

A complete AOD-9604 COA should include: peptide identity confirmation, HPLC purity (ideally above 98%), mass spectrometry molecular weight data matching approximately 1,817.08 daltons, amino acid composition, batch and lot number, synthesis date, storage conditions, and contact information for the independent third-party laboratory that performed the testing.

Is AOD-9604 legal to purchase for research?

In most jurisdictions including the United States, AOD-9604 is legal to purchase for qualified researchers conducting controlled laboratory research. It is not FDA-approved for human or veterinary clinical use. Regulatory status varies by country, so researchers should verify the rules applicable to their specific jurisdiction and institution before ordering.

What purity level is considered acceptable for AOD-9604 research use?

For reliable laboratory research, AOD-9604 purity of 98% or above as determined by reversed-phase HPLC is generally considered the acceptable threshold. Batches below this level introduce higher uncertainty into experimental results. Purity should always be reported with a supporting chromatogram, not as a standalone number without documentation.

Related in this series

• The Science of AOD-9604 Peptide: What Research Shows